Slingshot Insights | Abbv Overview

ABBV Overview

Upcoming Projects (ABBV)

Examining AnaptysBio's recent Phase 2b data on rosnilimab for the treatment of rheumatoid arthritis (RA)
Tickers: ANAB, LLY, PFE, ABBV
Execute By: Jun 30, 2025

Executed Projects (ABBV)

A Second Look: Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy
Tickers: KOD, ALPMF, APLS, ABBV
Executed On: May 23, 2025 at 03:30 PM EDT
Discussing Rinvoq's label expansion for patients with giant cell arteritis.
Ticker: ABBV
Executed On: May 22, 2025 at 11:00 AM EDT
Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy
Tickers: KOD, ALPMF, APLS, ABBV
Executed On: May 22, 2025 at 08:00 AM EDT
A prescriber check-in on AbbVie's Vyalev (foscarbidopa + foslevodopa) for Advanced Parkinson's Disease
Tickers: ABBV, SUPN, MSBHF
Executed On: Apr 25, 2025 at 11:00 AM EDT
Discussing current use of Cobenfy (KarXT) in treating patients with schizophrenia
Tickers: BMY, ABBV
Executed On: Apr 25, 2025 at 09:00 AM EDT
A Third Look: Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderate to severe Crohn's disease
Tickers: JNJ, ABBV, LLY
Executed On: Apr 02, 2025 at 09:30 AM EDT
Second Look: Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderate to severe Crohn's disease
Tickers: JNJ, ABBV, LLY
Executed On: Apr 01, 2025 at 04:00 PM EDT
Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderately to severely active Crohn's disease
Tickers: JNJ, ABBV, LLY
Executed On: Mar 31, 2025 at 03:00 PM EDT
A Third Opinion: Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 28, 2025 at 02:00 PM EST
A Second Opinion: Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 27, 2025 at 02:00 PM EST
Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 24, 2025 at 02:00 PM EST
Examining the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Tickers: ABBV, CERE
Executed On: Feb 13, 2025 at 04:00 PM EST
Discussing the upcoming phase 3 readout of povorcitinib in Hidradenitis Suppurativa, as well as other investigational agents including upadacitinib and sonelokimab
Tickers: INCY, ABBV, MLTX
Executed On: Jan 30, 2025 at 10:00 AM EST
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences January 2025
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: Jan 23, 2025 at 12:31 PM EST
Quarterly Survey: Frown Line Injection Treatments including Crown Laboratories' Daxxify and ABBV's Botox January 2025
Tickers: CROWN LABORATORIES, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jan 22, 2025 at 10:55 AM EST
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences October 2024
Tickers: ABBV, ESTA, JNJ, SIEN
Executed On: Oct 24, 2024 at 05:34 PM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify October 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics, Crown Laboratories
Executed On: Oct 22, 2024 at 12:05 PM EDT
A look at the data presented at ESMO for ovarian cancer treatments including the Phase 2 PICCOLO trial of Elahere in PSOC.
Tickers: ABBV, AZN, GMAB, 600276.XSHG
Executed On: Oct 22, 2024 at 09:30 AM EDT
Discussing the AMPLIFY Phase III trial of Calquence plus venetoclax as a first line treatment for chronic lymphocytic leukemia
Tickers: AZN, ABBV, RHHBY
Executed On: Aug 29, 2024 at 12:00 PM EDT
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences July 2024
Tickers: ABBV, ESTA, JNJ, SIEN
Executed On: Jul 26, 2024 at 12:24 PM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jul 26, 2024 at 12:20 PM EDT
Discussing the IRAK4 degrader KT-474/SAR444656 from Kymera/Sanofi and the potential in HS (Hidradenitis suppurativa) and AD (atopic dermatitis)
Tickers: KYMR, REGN, LLY, SNY, ABBV
Executed On: Jul 18, 2024 at 11:00 AM EDT
Examining the market potential of AbbVie's EPKINLY® (epcoritamab-bysp) for relapsed/refractory follicular lymphoma
Ticker: ABBV
Executed On: Jul 17, 2024 at 11:00 AM EDT
Discussing current treatment options for CLL and the potential of Nurix Therapeutics' NX-5948, a BTK degrader
Tickers: NRIX, ABBV, BGNE, AZN, LLY
Executed On: Jul 12, 2024 at 10:00 AM EDT
A Second Opinion: Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 20, 2024 at 02:30 PM EDT
Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 12, 2024 at 11:00 AM EDT
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences April 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: May 01, 2024 at 11:05 AM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Apr 18, 2024 at 12:52 PM EDT
A discussion of BTK inhibitors in Chronic Lymphocytic Leukemia, including zanabrutinib and NX-5948
Tickers: BGNE, ABBV, NRIX
Executed On: Jan 26, 2024 at 02:00 PM EST
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences January 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: Jan 24, 2024 at 12:43 PM EST
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jan 19, 2024 at 10:48 AM EST
Investigating the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo.
Tickers: ABBV, INCY
Executed On: Nov 22, 2023 at 08:30 AM EST
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify October 2023
Tickers: RVNC, ABBV
Executed On: Oct 31, 2023 at 12:02 PM EDT
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences October 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Oct 31, 2023 at 11:28 AM EDT
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences July 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Aug 02, 2023 at 10:52 AM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2023
Tickers: RVNC, ABBV, IPN, EOLS
Executed On: Jul 31, 2023 at 03:46 PM EDT
Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, ABBV
Executed On: Jul 13, 2023 at 11:00 AM EDT
A Second Look: Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 12, 2023 at 11:00 AM EDT
Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 06, 2023 at 05:00 PM EDT
Delving into the data from the SLEek clinical trial on Abbvie's RINVOQ (upadacitinib) in treating patients with Systemic Lupus Erythematosus.
Ticker: ABBV
Executed On: Jun 06, 2023 at 03:15 PM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2023
Tickers: RVNC, ABBV, IPN
Executed On: Apr 19, 2023 at 12:15 PM EDT
Quarterly Survey: Breast Implants April 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Apr 14, 2023 at 03:38 PM EDT
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2023
Tickers: RVNC, ABBV, IPN
Executed On: Feb 14, 2023 at 12:43 PM EST
Quarterly Survey: Breast Implants February 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Feb 07, 2023 at 06:12 PM EST

Expired Projects (ABBV)

A Look at Novartis' Cosentyx in treating Hidradenitis Suppurativa and how it can compete with Humira
Tickers: NVS, ABBV, ANAB
Execute By: Aug 08, 2022
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016

Upcoming & Overdue Catalysts (ABBV)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ABBV)

AbbVie 's (ABBV) Phase 3 Trial Evaluating Veliparib (ABT-888) in Treatment of Patients with Ovarian Cancer Expected to Conclude in January 2019
Ticker: ABBV
Occurred on: Nov 10, 2019
AbbVie's (ABBV) RINVOQ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis, Receives FDA Approval
Ticker: ABBV
Occurred on: Aug 16, 2019
Rova-T (TRINITY) Phase 2 pivotal data in Third-line Small Cell Lung Cancer expected Q4 2017
Ticker: ABBV
Occurred on: Mar 22, 2018
Phase 3 Topline data of Neurocrine's (NBIX) Elagolix in treating Uterine Fibroids expected Q1 2018
Tickers: NBIX, ABBV
Occurred on: Feb 21, 2018
Abbvie's(ABBV) Upadacitinib (ABT-494) as Monotherapy Results released in Phase 3 Rheumatoid Arthritis Study
Ticker: ABBV
Occurred on: Dec 20, 2017
Phase 3 data of AbbVie's(ABBV) Risankizumab in Psoriasis due by the end of 2017 due by the end of 2017
Ticker: ABBV
Occurred on: Oct 26, 2017
NDA for Elagolix in treating Endometriosis anticipated in 3rd Quarter 2017
Tickers: ABBV, NBIX
Occurred on: Sep 06, 2017
AbbVie (ABBV) Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Ticker: ABBV
Occurred on: Sep 06, 2017
AbbVie/Enata Hepatitis C Drug, Glecaprevir/Pibrentasvir (G/P), PDUFA Approximately 8/2/2017
Tickers: ABBV, ENTA
Occurred on: Aug 03, 2017
Data available 2H from Phase III study of Empliciti in first-line multiple myeloma
Tickers: BMY, ABBV
Occurred on: Jun 24, 2017
AbbVie commences Phase 3 trial of ABT-494 for rheumatoid arthritis, expected completion mid-2017
Ticker: ABBV
Occurred on: Jun 07, 2017
AbbVie (ABBV) Phase 2 Data Evaluating ABT-494 in Crohn's Disease Expected in H1 2017
Ticker: ABBV
Occurred on: May 09, 2017
Dr. Reddy (RDY) Launches Generic Version of AbbVie's (ABBV) Prometrium (Progesterone USP) in U.S
Tickers: RDY, ABBV
Occurred on: Apr 25, 2017
AbbVie (ABBV) Phase 3 ENDURANCE-3 Data Evaluating Glecaprevir/Pibrentasvir in Difficult-to-Treat Genotype 3 HCV Patients Without Cirrhosis
Ticker: ABBV
Occurred on: Apr 21, 2017
AbbVie (ABBV) Phase 3 EXPEDITION-1 Results Evaluating Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection With Genotypes 1,2,4,5 or 6 and Compensated Cirrhosis
Ticker: ABBV
Occurred on: Apr 20, 2017
AbbVie (ABBV) Reports Data Phase 3 Data Evaluating Veliparib in Non-Small Cell Lung Cancer and Triple Negative Breast Cancer
Ticker: ABBV
Occurred on: Apr 19, 2017
Japaense Ministry of Health Grants Priority Review to AbbVie's (ABBV) Marketing Application for Glecaprevir/Pibrentasvir (G/P) in Treatment of Hepatitis C Virus (HCV) Infection
Ticker: ABBV
Occurred on: Mar 14, 2017
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Recommends Approval for AbbVie's (ABBV) Shorter Regimen of Viekirax + Exviera in HCV-1b Infection
Ticker: ABBV
Occurred on: Feb 27, 2017
AbbVie (ABBV) Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
Ticker: ABBV
Occurred on: Jan 25, 2017
U.S. FDA Approves IMBRUVICA (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Ticker: ABBV
Occurred on: Jan 19, 2017
AbbVie (ABBV) Announces Top-Line Data from Phase 3 CERTAIN-1 Study Evaluating Ribavirin-Free Regimen of Glecaprevir and Pibrentasvir (G/P) in Japanese Patients with Genotype 1 Chronic Hepatitis C virus (HCV) Infection Without Cirrhosis
Tickers: ABBV, ENTA
Occurred on: Jan 09, 2017
AbbVie's Main US Patent on HUMIRA (adalimumab) to expire in December 2016, Still Protected by Dozens of Other Patents
Ticker: ABBV
Occurred on: Dec 31, 2016
AbbVie (ABBV) Submits NDA to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Ticker: ABBV
Occurred on: Dec 19, 2016
Janssen (JNJ) Initiates Phase 2b Study Evaluating Simeprevir/Odalasvir/JNJ-4178 in Chronic Hepatitis C Virus Infection Genotypes 1,2,4,5 and 6 Without Cirrhosis
Tickers: JNJ, GILD, ABBV
Occurred on: Nov 28, 2016
Regeneron (REGN) and Sanofi (SNY) Announce Phase 3 SARIL-RA-MONARCH Results Evaluating Sarilumab Compared to AbbVie's (ABBV) Humira in Rheumatoid Arthritis (RA)
Tickers: REGN, ABBV, SNY
Occurred on: Nov 16, 2016
AbbVie (ABBV) Releases Results from Three Pivotal Studies of Pan-Genotypic Chronic Hepatitis B Virus Infection Regimen Glecaprevir/Pibrentasvir to be Presented at The Liver Meeting in Boston, November 11 - 15
Ticker: ABBV
Occurred on: Nov 15, 2016
AbbVie's (ABBV) HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Ticker: ABBV
Occurred on: Nov 14, 2016
U.S. Patent Office's Patent Trial and Appeal Board (PTAB) Denies Coherus (CHRS) Petition for Inter Partes Review of AbbVie's (ABBV) U.S. Patent No. 9,114,166 for HUMIRA
Tickers: CHRS, ABBV
Occurred on: Nov 07, 2016
Boehringer Ingelheim Announces Phase 3 Results for Humira Biosimilar Candidate in Active Rheumatoid Arthritis
Tickers: BOEHRINGER INGELHEIM, ABBV
Occurred on: Oct 26, 2016
AbbVie (ABBV) Presents Data From Two Phase 3 Trails Evaluating Elagolix in Premenopausal Women with Endometriosis
Ticker: ABBV
Occurred on: Oct 19, 2016
FDA Announces Black Box Requirement for Risk of HBV Reactivation for at Least 9 Brand Name Drugs in Hepatitis C Treatment
Tickers: GILD, ABBV, MRK
Occurred on: Oct 05, 2016
AbbVie's (ABBV) Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Ticker: ABBV
Occurred on: Sep 30, 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Ticker: ABBV
Occurred on: Sep 23, 2016
AbbVie files patent lawsuit seeking to stop Amgen’s copy of Humira
Tickers: ABBV, AMGN
Occurred on: Aug 05, 2016
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Ticker: ABBV
Occurred on: Jul 28, 2016
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
Ticker: ABBV
Occurred on: Jul 25, 2016
AbbVie Receives Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Ticker: ABBV
Occurred on: Jul 11, 2016
AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress
Ticker: ABBV
Occurred on: Jul 07, 2016
Biogen and AbbVie’s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Tickers: BIIB, ABBV
Occurred on: Jul 05, 2016
AbbVie's HUMIRA (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
Ticker: ABBV
Occurred on: Jun 30, 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosis
Tickers: ABBV, BIIB
Occurred on: May 27, 2016
AbbVie's HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Ticker: ABBV
Occurred on: May 27, 2016
EMA Decision on Regulatory Filings for Empliciti for Approval in Europe Due by April 1
Tickers: BMY, ABBV
Occurred on: May 11, 2016
AbbVie Receives FDA Accelerated Approval of Venclexta (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Tickers: ABBV, RHHBY
Occurred on: Apr 11, 2016
FDA Priority Review date for Venetoclax Set mid-2016
Ticker: ABBV
Occurred on: Apr 11, 2016
U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
Tickers: JNJ, ABBV, Janssen Biotech
Occurred on: Mar 04, 2016
IMBRUVICA (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia
Ticker: ABBV
Occurred on: Mar 04, 2016
Abbvie recieves CHMP positive opinion for Viekirax + Exviera withthout Ribavirin in treating HCV in GT1B patients with compensated cirrhosis in Europe
Ticker: ABBV
Occurred on: Feb 26, 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Ticker: ABBV
Occurred on: Feb 26, 2016
Three more Phase 3 clinical trials of ABT-494 will begin enrollment in early 2016 and will include patients with an inadequate response to biologics and patients who are MTX-naive
Ticker: ABBV
Occurred on: Feb 19, 2016
AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
Ticker: ABBV
Occurred on: Feb 10, 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy)
Ticker: ABBV
Occurred on: Jan 27, 2016
AbbVie and Roche's venetoclax gets new Breakthrough Therapy tag for blood cancer
Tickers: ABBV, SWX: RO
Occurred on: Jan 20, 2016
Priority review from FDA and Marketing Authorization Application from EMA granted for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia. It's NDA has been accepted by FDA and EMA
Ticker: ABBV
Occurred on: Jan 12, 2016
AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies evaluating its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530
Ticker: ABBV
Occurred on: Jan 11, 2016
Abbvie announced the start of a large Phase 3 clinical trial program to study the use of ABT-494, an investigational, once-daily, oral selective JAK1 inhibitor for the treatment of rheumatoid arthritis
Ticker: ABBV
Occurred on: Jan 08, 2016
Bristol-Myers Squibb (BMY) to Present Data from Several Studies on Hepatitis C Patients at Annual Meeting of The American Association for the Study of Liver Diseases 2015
Tickers: BMY, GILD, ABBV
Occurred on: Nov 17, 2015
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Tickers: LLY, ABBV
Occurred on: Nov 08, 2015
Lilly (LLY) and Incyte (INCY) Announce Data from Phase 3 RA-BEGIN Study Demonstrating Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Patients Treated With Baricitinib Compared with Adalimumab
Tickers: INCY, ABBV, LLY
Occurred on: Nov 07, 2015

Strategic Initiatives (ABBV)

AbbVie (ABBV) and I-Mab (IMAB) Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Tickers: ABBV, IMAB
Announcement Date: Sep 04, 2020
FTC has voted 3-1-1 approving a final order settling charges that AbbVie's (ABBV) $63B takeover of Allergan (AGN) would violate federal antitrust law
Ticker: ABBV
Announcement Date: Sep 04, 2020
AbbVie (ABBV) Agrees to Collaborate with BioArtic to Develop Treatments for Neurodegenerative Diseases Including Parkinson's
Tickers: ABBV, BioArtic
Announcement Date: Sep 20, 2016
X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership
Tickers: ABBV, X-Chem
Announcement Date: Jul 26, 2016
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Tickers: BMY, ABBV
Announcement Date: Jul 25, 2016
AbbVie buys Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
Ticker: ABBV
Announcement Date: Apr 28, 2016
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Tickers: ABBV, Boehringer Ingelheim
Announcement Date: Mar 07, 2016
Philogen announces expanded research and development agreement with Abbvie
Tickers: ABBV, Philogen S.p.A.
Announcement Date: Feb 15, 2016